Interleukin-6 in rheumatoid arthritis

@article{Nishimoto2006Interleukin6IR,
  title={Interleukin-6 in rheumatoid arthritis},
  author={Norihiro Nishimoto},
  journal={Current Opinion in Rheumatology},
  year={2006},
  volume={18},
  pages={277–281}
}
  • N. Nishimoto
  • Published 1 May 2006
  • Medicine, Biology
  • Current Opinion in Rheumatology
Purpose of reviewRecent progress in cytokine studies has clarified the pathological roles played by cytokines and provided key evidence that antagonizing their actions can be therapeutic. The pathogenesis of rheumatoid arthritis, an autoimmune inflammatory disease, involves inflammatory cytokines such as tumour necrosis factor-α, interleukin-1 and interleukin-6. Anti-tumour necrosis factor-α and anti-interleukin-1 therapies have been used successfully to treat rheumatoid arthritis, but they are… 
View on Wolters Kluwer
ncbi.nlm.nih.gov
195 Citations
Highly Influential Citations
7
Background Citations
87
Methods Citations
1
Results Citations
1

195 Citations

Citation Type

Citation Type

Interleukin 6: from bench to bedside
TLDR
Blocking IL-6 actions by use of a humanized antibody, tocilizumab, which targets the IL- 6 receptor, has been proven to be therapeutically effective for rheumatoid arthritis, systemic juvenile idiopathic arthritis, Castleman disease and Crohn's disease.
Humanized antihuman IL-6 receptor antibody, tocilizumab.
TLDR
Tocilizumab is expected to ameliorate the autoimmune inflammatory diseases with IL-6 overproduction and has been clinically developed as a therapeutic agent for RA, systemic-onset and articular types of JIA, Crohn's disease, etc.
Specific Increase in Joint Neutrophil Extracellular Traps and Its Relation to Interleukin 6 in Autoimmune Arthritis
TLDR
The results suggest that IL-6 enhances neutrophil chemotaxis and NETosis in inflammatory joints and could be the source of citrullinated proteins.
Inflammatory pathways of importance for management of inflammatory bowel disease.
TLDR
The major signaling pathways of clinical importance for IBD therapy are elucidated and several new treatment options are under development for the treatment of CD and UC, however, no drug fits all patients.
Dissecting the contribution of B cells in an experimental model of rheumatoid arthritis
TLDR
It is described that an innate inflammatory stimulus, such as LPS, elicited joint pathology but was insufficient to breach B and T self-tolerance, and on the contrary, antigen-specific T cell activation led to arthritis and the production of several autoantibodies typical of RA.
Tocilizumab for the treatment of rheumatoid arthritis
TLDR
Clinical trials have shown that tocilizumab 8 mg/kg administered by monthly infusion not only improves clinical signs and symptoms of refractory rheumatoid arthritis but also suppresses radiographic progression.
Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018
TLDR
SRK is an IgG1κ human anti-IL-6 monoclonal antibody which binds to IL- 6 and prevents IL-6-mediated downstream effects and seems to be similar to TCZ, except for an increased mortality post open-label studies due to infections and cardiovascular events.
New drug discovery strategies for rheumatoid arthritis: a niche for nonhuman primate models to address systemic complications in inflammatory arthritis
TLDR
It is postulate that there is a specific niche for nonhuman primate models of inflammatory arthritis to address these systemic complications that occur in RA and these models in nonhuman primates can be valuable for studying disease-related aspects that cannot be addressed in rodent models.
PRO-INFLAMMATORY SIGNAL DELIVERED IN VITRO BY LEFLUNOMIDE ACTIVE METABOLITE A77 1726 ON ABNORMAL PERIPHERAL MONOCYTES IN RHEUMATOID ARTHRITIS
TLDR
It is pointed out that in particular circumstances, such as a high number of activated peripheral monocytes subjected to low concentrations of drugs, A77 1726 and to a lesser extent MTX, may sustain the systemic inflammatory process in rheumatoid arthritis.
Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis
TLDR
Findings indicate that the expression pattern of immunohistochemical findings in synovium was changed in effect attenuation cases among RA patients treated with infliximab.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
TLDR
Treatment with MRA was generally well tolerated and significantly reduced the disease activity of RA, and the adverse events were not dose dependent.
Interleukin 6 Is Required for the Development of Collagen-induced Arthritis
TLDR
It is suggested that IL-6 receptor antagonists might be beneficial for the treatment of RA, accompanied by a reduced antibody response to type II collagen and the absence of inflammatory cells and tissue damage in knee joints.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
TLDR
In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotRexate provided clinical benefit and halted the progression of joint damage.
Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides.
TLDR
There is a significant correlation between serum IL-6 activity and serum levels of C-reactive protein, alpha 1-acid glycoprotein,alpha 1-antitrypsin, fibrinogen, and haptoglobin, which indicates that IL- 6 is related to disease activity in patients with RA.
Etanercept Therapy in Rheumatoid Arthritis
TLDR
This study sought to define further the clinical activity of etanercept over a longer treatment period and to establish a simplified dosing schema for rheumatoid arthritis.
Interleukin-6 in biology and medicine.
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
TLDR
IL-6 is the pivotal cytokine that induces VEGF production in synergy with IL-1beta or TNFalpha, and this may be the mechanism by which IL-6 blockade effectively suppresses VEGf production in synovial fibroblasts.
Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis.
TLDR
IL-6 produced after CII immunization appears to play an essential role in the immunity to CII, and anti-IL- 6R antibody reduces the development of CIA by suppressing IL-6 signal transduction.
Do We Need New Treatment That Goes beyond Tumor Necrosis Factor Blockers for Rheumatoid Arthritis?
  • R. Voll, J. Kalden
  • Medicine, Biology
    Annals of the New York Academy of Sciences
  • 2005
TLDR
To ameliorate painful joint inflammation and prevent disability in RA patients, new treatment principles and more intelligent combination therapies are urgently needed.
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
TLDR
This is the first randomized controlled trial showing that inhibition of IL-6 significantly improved the signs and symptoms of RA and normalized the acute-phase reactants.
...
1
2
3
4
...